Inventiva Receives $10 Million Milestone Payment from CTTQ

Inventiva, a clinical-stage biopharmaceutical company listed on Euronext Paris and Nasdaq, has announced the receipt of a $10 million milestone payment from Chia Tai-Tianqing Pharmaceutical Group (CTTQ), a Sino Biopharm subsidiary. This payment is connected to their collaborative agreement to develop and commercialize lanifibranor in certain Asian markets.

In 2022, Inventiva and CTTQ entered into an agreement to focus on the treatment of MASH, a chronic liver disease, with lanifibranor. Inventiva could receive up to $265 million in additional payments, along with royalty from annual net sales in specific regions. The partnership has seen progress with the successful Phase 1 bridging study, allowing further regulatory steps in China.

The receipt of this payment underscores the ongoing development efforts and the potential for future approvals and commercialization in the region.